ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop

Berry Consultants will again have a strong presence at this year’s ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop in Washington, D.C. on September 12-14, 2018.  Team members presenting are Scott Berry, Melanie Quintana and Tom Parke.  Scott Berry will be a part of the Friday, September 14th Parallel Session from 1:15 to 2:30pm, “Adaptive Enrichment Designs: New Methods and Clinical Applications”, where he will discuss the Bayesian adaptive DAWN stroke trial.

Melanie Quintana will be a part of the Friday, September 14th Parallel Session from 1:15 to 2:30 pm, “Innovations in Rare Disease Clinical Programs” where she will discuss Combining Clinical Progression Modeling with Innovative Trial Design in Rare Disease Trials.  Tom Parke will present the topic, “Evaluating Phase II Trial Designs by Estimating the Effect on the Net Present Value of the Development Program” during a Roundtable Discussion from 11:45am to 1:15pm on Thursday, September, 13.  To learn more and register to attend the event, please visit the workshop web page.

More Recent News

February 2024 QUOTES Webinar

Berry Consultants will be hosting a webinar on the optimization of a clinical trial design by estimating its impact on the expected net present value of a drug development program using the software QUOTES (Quantification and Optimization of Trial Expectations Simulator).

Blog: Precision Promise Adaptive Platform Trial update

Blog by: Kert Viele News from the Precision Promise platform trial. https://fibrogen.gcs-web.com/news-releases/news-release-details/fibrogen-announces-completion-pamrevlumab-arm-precision-promise Precision Promise is an adaptive platform trial investigating potential therapies for pancreatic cancer,

January 2024 FACTS Webinar

The Berry Consultants software team will be hosting its January FACTS webinar next Friday, January 19th at 11am EST to present the development plans for adding an ordinal endpoint option to the trial simulator.

Blog: Comments on the draft FDA master protocol guidance

Blog by: Kert Viele The FDA draft master protocol guidance is out https://www.fda.gov/regulatory-information/search-fda-guidance-documents/master-protocols-drug-and-biological-product-development Comments are due by February 22. Here are some preliminary thoughts and